Atul M. Desai, Hemshree A. Desai, Rutvij A. Desai, Chirag Desai
Atul M. Desai1*, Hemshree A. Desai2, Rutvij A. Desai3, Chirag Desai4
1Ayurveda Physician, Dhanvantari Clinic, Ayurveda Health Care and Research Centre, Vyara, Gujarat, India.
2Modern Medicine Practitioner
Dhanvantari Clinic, Ayurveda Health Care and Research Centre, Vyara, Gujarat, India.
3Student of Master of Science, Manila Central University, Philippines.
4Associate Professor: Department of Pharmacology, ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi.
Volume - 15,
Issue - 11,
Year - 2022
Indian traditional system of medicine has a definite role in the treatment of Covid-19. This case report presents the outcome of Ayurvedic interventions along with modern medicines in a severe covid-19 infected patient with breathlessness. A patient with a history of cough, breathing difficulty and generalized weakness tested positive for the rapid antigen test and prescribed the standard treatment of care with 14 days of strict home quarantine. During follow-up, there was no clinical improvement and oxygen saturation was fluctuating and required oxygen support. Therefore, the patient sought ayurvedic intervention at the covid-19 healthcare center with supportive oxygen therapy. The patient was managed with ayurvedic intervention along with modern medicines. On the date of admission to the covid-19 care center, the patient's SpO2 72% on room air, HRCT 80-90%, and ESR, CRP, and LDH were 40(mm/hour), 11.47(mg/L), and 306(Units/L) respectively. By adhering to the integrated therapy patient’s oxygen saturation and clinical profile were improved with time. On the 11th day of treatment patient, SpO2 was sustained at 95% and HRCT report was 70-80%, and clinical profile improved remarkably. The patient’s HRCT after one month was50-60% compared to the previous report suggestive of remarkable improvement. The effect on inflammatory markers and oxygen saturation suggests that integration of modern medicines along with ayurvedic medicine in the patient was significant and deserves further studies. Integrating ayurvedic treatment along with modern medicine might be considered as an effective approach in the management of severe covid-19 patients.
Cite this article:
Atul M. Desai, Hemshree A. Desai, Rutvij A. Desai, Chirag Desai. Case study on the effect of T-AYU-HM Premium with modern medicine in severe Covid-19 Patient. Research Journal of Pharmacy and Technology. 2022; 15(11):4950-4. doi: 10.52711/0974-360X.2022.00832
Atul M. Desai, Hemshree A. Desai, Rutvij A. Desai, Chirag Desai. Case study on the effect of T-AYU-HM Premium with modern medicine in severe Covid-19 Patient. Research Journal of Pharmacy and Technology. 2022; 15(11):4950-4. doi: 10.52711/0974-360X.2022.00832 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-17
1. Hippich M, Holthaus L, Assfalg R, et al. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y). 2021;2(2):149-163.e4. doi:10.1016/j.medj.2020.10.003
2. Jalali SF, Ghassemzadeh M, Mouodi S, et al. Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran. Caspian J Intern Med. 2020;11(Suppl 1):544-550. doi:10.22088/cjim.11.0.544
3. Desai A, Desai K, Desai H, et al. Effectiveness report of T-AYU-HM premium and onion vaporization on corona positive sickle cell anemia patients: a case study. Int. J. Pharm. Sci. Drug Res. 2021; 13(1):99-102. DOI: 10.25004/IJPSDR.2021.130115
5. Zaid Y, Puhm F, Allaeys I, et al. Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19 [published online ahead of print, 2020 Sep 17]. Circ Res. 2020;127(11):1404-1418. doi:10.1161/CIRCRESAHA.120.317703
6. Canoglu K, Saylan B. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. Ann Saudi Med. 2020; 40(6):462-468. doi:10.5144/0256-4947.2020.462
7. Ahmed MH, Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review [published online ahead of print, 2020 Oct 31]. SN Compr Clin Med. 2020;1-10. doi:10.1007/s42399-020-00610-8
8. Zhao M, Shao Z, Liu H, Li K, Cao Z, et al. In-vitro effects of low-molecular weight heparin and dexamethasone on the hemolysis of red blood cells from paroxysmal nocturnal hemoglobinuria patients. ZhonghuaXue Ye Xue Za Zhi. 2002; 23(2):80-2. PMID: 12015076.
9. Akiyama O, Ito T, Ogata M, Okano H, et al. Clinical evaluation of cefpodoxime proxetil, a new oral cephem, in the treatment of respiratory tract infections with the special reference to community-acquired Streptococcus Pneumoniae infections. Jpn J Antibiot. 1995; 48(4):522-8. PMID: 7783315.
10. Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995). 2020; 48(4):169-179. doi:10.1080/21548331.2020.1772639
11. Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate. [Updated 2020 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557485/
12. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory mycoplasma pneumoniae pneumonia in children. Respir Care 2015; 60: 1469–75.
13. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995; 108:415–18.
14. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-665. doi:10.1016/j.jinf.2020.03.041.